JP4955659B2 - 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 - Google Patents
糖及びその類似体を骨格とする分子輸送体並びにその製造方法 Download PDFInfo
- Publication number
- JP4955659B2 JP4955659B2 JP2008508732A JP2008508732A JP4955659B2 JP 4955659 B2 JP4955659 B2 JP 4955659B2 JP 2008508732 A JP2008508732 A JP 2008508732A JP 2008508732 A JP2008508732 A JP 2008508732A JP 4955659 B2 JP4955659 B2 JP 4955659B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- compound
- side chain
- brs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 37
- 235000000346 sugar Nutrition 0.000 title description 18
- 150000001875 compounds Chemical class 0.000 claims description 189
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 75
- 125000006239 protecting group Chemical group 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 32
- 230000000975 bioactive effect Effects 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 28
- 150000005846 sugar alcohols Chemical class 0.000 claims description 28
- 238000005917 acylation reaction Methods 0.000 claims description 27
- 125000003277 amino group Chemical group 0.000 claims description 27
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 26
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 229960000367 inositol Drugs 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 16
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 15
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 150000002016 disaccharides Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical group OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 125000000185 sucrose group Chemical group 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 229930195727 α-lactose Natural products 0.000 claims description 3
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 2
- 125000003071 maltose group Chemical group 0.000 claims description 2
- 229930195724 β-lactose Natural products 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 5
- 241000023320 Luma <angiosperm> Species 0.000 claims 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims 3
- 210000005260 human cell Anatomy 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 238000006243 chemical reaction Methods 0.000 description 51
- 239000011734 sodium Substances 0.000 description 43
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- 108010078791 Carrier Proteins Proteins 0.000 description 41
- 239000000543 intermediate Substances 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- 239000007787 solid Substances 0.000 description 35
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 238000002360 preparation method Methods 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 238000004440 column chromatography Methods 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- -1 t-butyldiphenylsilyl (TBDPS) group Chemical group 0.000 description 18
- 230000035699 permeability Effects 0.000 description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 210000000170 cell membrane Anatomy 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 14
- 229960002920 sorbitol Drugs 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- VPWFNCFRPQFWGS-UHFFFAOYSA-N tert-butyl n-[amino-[(2-methylpropan-2-yl)oxycarbonylamino]methylidene]carbamate Chemical group CC(C)(C)OC(=O)NC(N)=NC(=O)OC(C)(C)C VPWFNCFRPQFWGS-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000007789 gas Substances 0.000 description 8
- LQLJNIMZZWZZLE-UHFFFAOYSA-N 4-(iminomethylideneamino)-n,n-dimethylpentan-1-amine;hydrochloride Chemical compound Cl.N=C=NC(C)CCCN(C)C LQLJNIMZZWZZLE-UHFFFAOYSA-N 0.000 description 7
- 0 CCC1(O)OC(C*)C(*)C1* Chemical compound CCC1(O)OC(C*)C(*)C1* 0.000 description 7
- 125000000129 anionic group Chemical group 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 229960002684 aminocaproic acid Drugs 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 210000000633 nuclear envelope Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 125000004404 heteroalkyl group Chemical group 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical group CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical group OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 150000004001 inositols Chemical class 0.000 description 4
- 239000008101 lactose Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- RUFDYIJGNPVTAY-UHFFFAOYSA-N 6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCCCC(O)=O RUFDYIJGNPVTAY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010043958 Peptoids Proteins 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- PKPZOLMERRZNAI-UHFFFAOYSA-N 2-(azidomethyl)-4,4,4-trifluorobutanoic acid Chemical compound FC(CC(C(=O)O)CN=[N+]=[N-])(F)F PKPZOLMERRZNAI-UHFFFAOYSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LDPFQVWIUACVFE-SVIIGIRWSA-N 2,3:5,6-di-o-isopropylidene-myo-inositol Chemical compound OC1[C@@H]2OC(C)(C)O[C@H]2C(O)[C@H]2OC(C)(C)O[C@H]21 LDPFQVWIUACVFE-SVIIGIRWSA-N 0.000 description 1
- PDIDPCVGCQYPGY-UHFFFAOYSA-N 2-(bromomethyl)-4,4,4-trifluorobutanoic acid Chemical compound OC(=O)C(CBr)CC(F)(F)F PDIDPCVGCQYPGY-UHFFFAOYSA-N 0.000 description 1
- HNTRJVKMULLOIF-UHFFFAOYSA-N 2-(propylamino)hexanoic acid Chemical class CCCCC(C(O)=O)NCCC HNTRJVKMULLOIF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- APLNAFMUEHKRLM-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)N=CN2 APLNAFMUEHKRLM-UHFFFAOYSA-N 0.000 description 1
- YEXNNJWRYPGWGU-UHFFFAOYSA-N 2-amino-7-[(2-methylpropan-2-yl)oxy]-7-oxoheptanoic acid Chemical compound CC(C)(C)OC(=O)CCCCC(N)C(O)=O YEXNNJWRYPGWGU-UHFFFAOYSA-N 0.000 description 1
- IHBVNSPHKMCPST-UHFFFAOYSA-N 3-bromopropanoyl chloride Chemical compound ClC(=O)CCBr IHBVNSPHKMCPST-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- JBIXJXDWBBUPRB-UHFFFAOYSA-N C(=O)(OC(C)(C)C)NC(SC)=NC(=O)OC(C)(C)C.C(=O)(OC(C)(C)C)NC(SC)=NC(=O)OC(C)(C)C Chemical compound C(=O)(OC(C)(C)C)NC(SC)=NC(=O)OC(C)(C)C.C(=O)(OC(C)(C)C)NC(SC)=NC(=O)OC(C)(C)C JBIXJXDWBBUPRB-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- KYNIIJHTACNXNG-CCWIZYANSA-N O([C@H]1O[C@@H]([C@H]([C@H](OC(=O)C=2C=CC=CC=2)[C@H]1OC(=O)C=1C=CC=CC=1)O[C@H]1[C@@H]([C@@H](OC(=O)C=2C=CC=CC=2)[C@@H](OC(=O)C=2C=CC=CC=2)[C@@H](COC(=O)C=2C=CC=CC=2)O1)OC(=O)C=1C=CC=CC=1)COC(=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 Chemical compound O([C@H]1O[C@@H]([C@H]([C@H](OC(=O)C=2C=CC=CC=2)[C@H]1OC(=O)C=1C=CC=CC=1)O[C@H]1[C@@H]([C@@H](OC(=O)C=2C=CC=CC=2)[C@@H](OC(=O)C=2C=CC=CC=2)[C@@H](COC(=O)C=2C=CC=CC=2)O1)OC(=O)C=1C=CC=CC=1)COC(=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 KYNIIJHTACNXNG-CCWIZYANSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000015909 regulation of biological process Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Description
R1及びR2は、それぞれ独立に、水素、アルキル、アリールアルキル、シクロアルキル、ヘテロアルキル、−(CH2)mNHR’、−(CH2)lCO2R’’、−COR’’’、−SO2R’’’’または生理活性分子であり;R’、R’’、R’’’及びR’’’’はそれぞれ独立に、水素、アルキル、アリールアルキル、シクロアルキル、ヘテロアルキルまたは生理活性分子であり;mは2から5の整数;およびlは1から5の整数であり;
R3は、
R1及びR2はそれぞれ独立に、水素、アルキル、アリールアルキル、シクロアルキル、ヘテロアルキル、−(CH2)mNHR’、−(CH2)lCO2R’’、−COR’’’、−SO2R’’’’または生理活性分子であり;R’、R’’、R’’’及びR’’’’は、それぞれ独立に、水素、アルキル、アリールアルキル、シクロアルキル、ヘテロアルキルまたは生理活性分子であり;mは2から5の整数;およびlは1から5の整数であり;
R3は、
1)ヒドロキシル基のアシル化反応を通じてアミノ酸側鎖を導入して中間体化合物を得る段階;
2)段階1)で得た化合物のアミノ酸側鎖の末端アミノ基に、保護されたグアニジン基を導入する段階;及び
3)段階2)で得た化合物からグアニジン基の保護基を除去し、分子輸送体化合物を提供する段階。
1)保護された中間体のヒドロキシル基にアシル化反応によってアミノ酸側鎖を導入する段階;
2)前記末端アミノ酸側鎖から保護基を除去する段階;
3)前記アミノ酸側鎖の末端アミノ基にグアニジン基を導入する段階;
4)前記段階3)で得た化合物のヒドロキシル基から保護基を除去し、生理活性分子に結合させる段階;及び
5)前記段階4)で得た化合物のグアニジン基からアミノ保護基を除去する段階。
1H−NMR(CD3OD):δ3.25−3.38(m,4H),3.59(t,J=9.2Hz,1H),3.94(m,1H),5.13(d,J=3.7Hz,2H),7.11−7.30(m,9H),7.42(d,J=9.4Hz,6H)
MS(FAB)m/z445.22(M++Na)。
1H−NMR(CD3OD):δ3.25−3.33(m,4H),3.47−3.51(m,2H),3.85−3.87(m,2H),7.14−7.26(m,9H),7.42(d,J=8.8Hz,6H)
MS(FAB)m/z447.29(M++Na)。
1H−NMR(CDCl3):δ1.06(s,9H),2.72(brs,1H),3.01(brs,1H),3.21(brs,1H),3.35(d,J=5.5Hz,2H),3.73−3.83(m,6H),7.22−7.65(m,25H)
MS(FAB)m/z686.24(M++Na)。
1H−NMR(CDCl3):δ1.35−1.49(m,4H),1.65(t,J=7.5Hz,2H),2.36(t,J=7.3Hz,2H),2.46−2.84(m,6H),2.86(t,J=6.7Hz,4H),10.35(brs,1H)
MS(FAB)m/z238.08(M++H)。
1H−NMR(CD3OD):δ1.31−1.68(m,6H),1.89(m,4H),2.22(t,J=7.2Hz,2H),2.71−2.76(m,6H),2.98(t,J=7.5Hz,4H)
MS(FAB)m/z246.15(M++H)。
1H−NMR(CDCl3):δ1.33−1.61(m,6H),1.94(brs,4H),2.27(t,J=6.8Hz,2H),2.93(brs,6H),3.20−3.22(m,4H),5.01(s,4H),5.65(brs,2H),7.31(brs,10H)
MS(FAB)m/z514.21(M++H)。
1H−NMR(CDCl3):δ1.30−1.62(m,6H),2.30(t,J=7.4Hz,2H),2.50(t,J=6.8Hz,6H),2.80−2.86(m,4H),3.66(s,6H)
MS(FAB)m/z304.18(M++H)。
1H−NMR(CD3OD):δ1.26−1.64(m,6H),2.16−2.22(m,2H),2.27−2.56(m,6H),2.71−2.88(m,8H),3.29−3.31(m,4H)
MS(FAB)m/z382.19(M++Na)。
1H−NMR(CD3OD):δ1.23−1.71(m,6H),2.13(t,J=6.8Hz,2H),2.30−2.48(m,6H),2.69(brs,4H),3.21−3.26(m,8H),5.04(s,4H),7.31−7.32(m,10H)
MS(FAB)m/z650.19(M++Na)。
1H−NMR(CDCl3):δ1.45−1.66(m,42H),2.41−2.44(m,6H),2.84(brs,4H),3.40−3.54(m,10H),8.18(brs,2H),8.64(brs,2H),11.44(brs,2H)
MS(FAB)m/z844.33(M++H)。
1H−NMR(CDCl3):δ3.05(t,J=6.7Hz,2H),3.60(t,J=6.7Hz,2H),4.54(q,J=8.4Hz,2H)。
1H−NMR(CDCl3):δ2.70(t,J=6.4Hz,2H),3.63(t,J=6.4Hz,2H),4.54(q,J=8.4Hz,2H)。
m.p=124〜126℃
[α]D=+113(c0.8、クロロホルム)
1H−NMR(CDCl3):δ3.73−3.86(m,2H,H−4&H−5’),3.94(t,J=6.7Hz,1H,H−5),4.32−4.47(m,2H,H−6’),4.60(s,2H,H−6),4.99(d,J=7.9Hz,1H,H−1’),5.42(dd,J=10.3Hz,3.3Hz,1H,H−3’),5.66(dd,J=10.3Hz,3.7Hz,1H,H−2),5.78−5.84(m,2H,H−2’&H−4’),6.25(t,J=9.9Hz,1H,H−3),6.79(d,J=3.7Hz,1H,H−1),7.20−8.16(m,40H,arom)。
1H−NMR(CDCl3):δ3.73−3.86(m,2H,H−4&H−5’),4.07−4.11(m,H−5’α&H−5’β),4.23−4.37(m,H−6’),4.44−4.56(m,H−6),4.90(d,J=8.0Hz,H−1’β),4.94(d,J=7.9Hz,1H,H−1’α),5.26(dd,J=10.2Hz,3.5Hz,H−3’α&H−3’β),5.34(d,J=1.7Hz,H−1β),5.41(dd,J=10.3Hz,3.1Hz,H−2α&H−2β),5.64(d,J=2.5Hz,1H,H−1α),5.70−5.76(m,H−4’α and H−2’α),5.81(t,J=9.0Hz,H−3β),6.18(t,J=9.5Hz,1H,H−3α),7.16−7.98(m,35H,arom)
MS(FAB)m/z1093.27(M++Na)。
1H−NMR(CDCl3):δ1.48(s、24H)、2.35(t、J=7.4Hz、2H)、3.38(brs、2H)、8.36(brs、1H、NH)、8.6−10.7(brs、2H、NH、OH)。
1H−NMR(CDCl3):δ1.01(s,9H),1.17−1.51(m,40H),1.86−2.32(m,32H),3.31(brs,16H),3.60−3.88(m,2H),3.93−4.12(m,2H),4.79−4.92(m,2H),4.98(s,16H),5.59(brs,8H),5.61−5.88(m,2H),7.13−7.59(m,65H)
MS(MALDI−TOF)m/z2668.40(M++Na)。
1H−NMR(CD3OD):δ1.02(s,9H),1.16−1.82(m,24H),2.07−2.38(m,24H),3.03−3.28(m,40H),3.56−3.80(m,2H),3.91−4.13(m,2H),4.87−5.13(m,2H,merged with CD3OD peak),5.88(dd,J=14.2Hz,1.9Hz,2H),7.24−7.68(m,25H)
MS(MALDI−TOF)m/z1593.89(M++Na)。
1H−NMR(CDCl3):δ1.03(s,9H),1.18−1.54(m,168H),2.28−2.64(m,24H),2.78−3.28(m,24H),3.59(brs,16H),3.89−4.21(m,4H),4.82(brs,1H),5.11(brs,1H),5.63(brs,1H),5.89(brs,1H),7.26−7.67(m,25H),8.39(brs,8H),11.35(brs,8H)
MS(MALDI−TOF)m/z3533.34(M++Na)。
1H−NMR(CDCl3):δ1.01(s,9H),1.12−1.59(m,168H),2.22−2.60(m,24H),2.77−3.33(m,24H),3.57(brs,16H),3.88−4.21(m,4H),4.80(brs,1H),5.13(brs,1H),5.66(brs,1H),5.88(brs,1H),7.25−7.68(m,10H),8.33(brs,8H),11.42(brs,8H)
MS(MALDI−TOF)m/z3291.13(M++Na)。
1H−NMR(CDCl3):δ1.02(s,9H),1.13−1.61(m,168H),2.11−2.45(m,24H),2.88(brs,6H),3.06−3.36(m,24H),3.57(brs,16H),3.88−4.21(m,4H),4.80(brs,1H),5.13(brs,1H),5.66(brs,1H),5.80(brs,1H),7.14(d,J=7.4Hz,1H),7.22−7.78(m,27H),8.16−8.19(m,2H),8.39(brs,8H),11.45(brs,8H)
MS(MALDI−TOF)m/z3523.44(M++Na)。
1H−NMR(CD3OD):δ1.01(s,9H),1.23−1.81(m,40H),1.98(brs,16H),2.27(brs,8H),2.81(s,6H),3.19−3.25(m,24H),3.88−4.21(m,4H),4.84(brs,1H),5.18(brs,1H),5.60(brs,1H),5.81(brs,1H),7.13−7.78(m,13H),8.16(brs,2H),8.44(brs,1H)
MS(MALDI−TOF)m/z1922.52(M++Na)
UVλmax(H2O,25℃)334nm。
1H−NMR(CDCl3):δ1.01(s,9H),1.40−1.53(m,168H),2.19−2.27(m,32H),2.66(brs.,16H),3.31−3.58(m,32H),3.63−3.92(m,2H),4.01(brs.,2H),4.23(brs.,1H),4.88−5.12(m,2H),5.48(brs,1H),5.73(brs,1H)7.16−7.58(m,25H),7.94(brs.,8H),8.51(brs.,8H),11.35(brs.,8H)
MS(MALDI−TOF)m/z3989.84(M++Na)。
1H−NMR(CDCl3):δ1.02(s,9H),1.33−1.55(m,168H),2.10−2.23(m,32H),2.68(brs,16H),3.28−3.55(m,32H),3.60−3.82(m,2H),3.97(brs,1H),4.20(brs,1H),4.77−5.09(m,2H),5.33(brs,1H),5.78(brs,1H),7.26−7.62(m,10H),7.92(brs,8H),8.36(brs,8H),11.45(brs,8H)。
1H−NMR(CDCl3):δ1.09(s,9H),1.44−1.56(m,168H),2.23(brs,32H),2.71(brs,16H),2.86(s,6H),3.37−3.52(m,32H),3.60−3.84(m,2H),4.01(brs,1H),4.23(brs,1H),4.77−5.11(m,2H),5.40(brs,1H),5.88(brs,1H),7.15(d,J=7.5Hz,1H),7.22−7.73(m,12H),7.89−8.14(m,10H),8.36(brs,9H),11.42(brs,8H)
MS(MALDI−TOF)m/z1483.99(M++Na)。
1H−NMR(CD3OD):δ1.01(s,9H),1.26−1.88(m,32H),2.11−2.32(m,16H),2.72(brs,16H),2.88(s,6H),3.27(brs,40H),3.66−3.93(m,4H),4.89−5.11(m,2H),5.56(brs,1H),5.88(brs,1H),7.15−7.74(m,13H),8.18(brs,2H),8.48(brs,1H)
MS(MALDI−TOF)m/z2145.35((M−C12H12NO2S)++Na)
UVλmax(H2O,25℃)336nm。
式16の中間体myo−イノシトールからアセトニド保護基を除去した後、前記実施例1−1〜1−6に記載された方法と同様に、脱保護した中間体をアシル化反応に供し、そこに側鎖を導入し、導入された側鎖のアミノ基をグアニジン基に変換させることによって8つのグアニジン基を有するイノシトール誘導体化合物(式7)を製造した。
式17の中間体myo−イノシトールからアセトニド保護基を除去した後、前記実施例1−1〜1−6に記載された方法と同様に、脱保護した中間体をアシル化反応に供し、そこに側鎖を導入し、導入された側鎖のアミノ基をグアニジン基に変換させ、8つのグアニジン基を有するイノシトール誘導体化合物(式8)を製造した。
式18の中間体myo−イノシトールからアセトニド保護基を除去した後、前記実施例1−1〜1−6に記載された方法と同様に、脱保護した中間体をアシル化反応に供し、そこに側鎖を導入し、導入された側鎖のアミノ基をグアニジン基に変換させ、8つのグアニジン基を有するイノシトール誘導体化合物(式9)を製造した。
1H−NMR(CD3OD):δ2.65(t,J=6.3Hz,2H,H),3.30−3.43(m,2H,H2,H4),3.59(t,J=6.3Hz,2H,Hα),3.65−3.83(m,7H,H5,H6α,H6’α,H’5,H6β,H3,H6’β),4.02−4.09(m,2H,H3’,H4’),4.21(d,J=12.0Hz,1H,H1’β),4.41(d,J=12.0Hz,H1’α),5.40(d,J=3.8Hz,1H,H1)
MS(FAB)m/z462.09(M++Na)。
1H−NMR(CDCl3):δ1.43(s,63H,7xt−Bu),1.72−1.87(m,14H),2.28−2.49(m,14H),2.66(t,J=6.3Hz,2H,Hβ),3.11−3.15(m,14H),3.62(t,J=6.3Hz,2H,Hα),4.16−4.34(m,8H),5.02−5.14(m,2H),5.37−5.46(m,3H),5.65(brs,1H)
MS(FAB)m/z1954.58(M++Na)。
1H−NMR(CD3OD):δ1.44−1.72(m,42H),2.44(brs,14H),2.70(brs,2H),2.96(brs,14H),3.62(m,2H),4.23−4.33(m,9H),5.12(brs,1H),5.38 5.61(m,3H),5.72(s,1H)
MS(FAB)m/z1231.94(M++H)。
1H−NMR(CDCl3):δ1.49(m,168H),2.23−2.42(m,14H),2.63−2.67(t,J=6.4Hz,2H),3.40−3.41(m,14H),3.59−3.63(t,J=6.4Hz,2H),4.22−4.33(m,6H),4.91(m,1H),5.08(m,1H),5.33−5.47(m,3H),5.62−5.63(m,1H),8.31(s,7H),11.50(s,7H)
MS(FAB)m/z2948.75(M++Na)。
1H−NMR(CDCl3):δ1.38−1.70(m,168H),2.23−2.36(m,14H),2.75−2.89(m,4H),3.04(brs,2H),3.40(s,14H),4.17−4.32(m,6H),4.92(d,1H),5.04−5.11(t,J=9.6Hz,1H),5.34−5.46(m,3H),5.62(s,1H),8.31(s,7H),11.50(s,7H)。
1H−NMR(CDCl3):δ1.45−1.59(m,168H),2.29−2.38(m,14H),2.60−2.70(brs,2H),2.89(s,6H),3.30−3.50(brs,14H),3.60−3.70(brs,2H),4.21−4.31(m,6H),5.00−5.15(brs,2H),5.35−5.48(m,4H),5.64(s,1H),7.18−7.20(d,J=7.0Hz,1H),7.52−7.55(m,2H),8.228.55(m,2H),8.31(s,7H),8.53−8.55(d,J=8.1Hz,1H),11.50(s,7H)。
1H−NMR(CD3OD):δ1.27−1.55(m,42H),2.24−2.44(m,16H),2.80(s,6H),3.07(brs,14H),3.40(brs,1H),3.55(brs,2H),4.12−4.24(m,6H),5.31−5.41(m,3H),5.58−5.63(m,1H),7.18−7.20(d,J=7.6Hz,1H),7.47−7.53(t,J=8.6Hz,2H),8.10−8.13(d,J=7.2Hz,1H),8.19−8.22(d,J=7.2Hz,1H),8.47−8.50(d,J=8.2Hz,1H)
MS(FAB)m/z1733.07(M++H)
UVλmax(H2O,25℃)318nm。
前記実施例6に記載された方法と同様に、製造例5で得た化合物にアシル化反応によってアミノ酸側鎖を導入し、側鎖のN末端にグアニジン基を導入し、7つのグアニジン基を有する二糖類誘導体化合物(式11、ラクトース骨格)を得た。
1H−NMR(CDCl3):δ1.28−1.60(m,90H),2.20−2.32(m,12H),3.02(brs,12H),4.04−4.11(m,2H),4.02(dd,J=14.6Hz,2.1Hz,1H),4.34(dd,J=14.8Hz,2.0Hz,1H),4.66(brs,6H),4.93(brs,1H),5.16(brs,1H),5.31−5.42(m,2H)
MS(MALDI−TOF)m/z1483.99(M++Na)。
1H−NMR(CD3OD):δ1.38−1.40(m,12H),1.59−1.63(m,24H),2.33(brs,12H),2.86(brs,12H),4.02−4.14(m,2),4.33−4.48(m,2H),5.11(brs,1H),5.23(brs,1H),5.44(brs,2H)
MS(MALDI−TOF)m/z861.80(M++H)。
1H−NMR(CDCl3):δ1.13−1.55(m,90H),2.23−2.26(m,12H),3.31−3.38(m,12H),4.04−4.06(m,2H),4.24(dd,J=2.3Hz,J=14.8Hz,2H),4.95(brs,1H),5.15(brs,1H),5.33−5.35(m,2H),8.26(brs,6H),11.45(brs,6H)
MS(MALDI−TOF)m/z2336.52(M++Na)。
1H−NMR(CD3OD):δ1.57(brs,36H),2.26(brs,12H),3.27(brs,12H),4.02−4.34(m,4H),5.09−5.33(m,4H)
MS(MALDI−TOF)m/z1113.77(M++H)。
1H−NMR(CDCl3):δ1.1−1.7(m,90H),2.17(app q,J=6.9Hz,10H),2.42(t,J=7.2Hz,2H),3.04(m,12H),4.81(broad s,6H,6 x NH),5.08(dd,J=10.4Hz,2.5Hz,2H),5.16(t,J=9.7Hz,1H),5.44(t,J=10.1Hz,2H),5.54(t,J=2.4Hz,1H)
MS(FAB)m/z1481.98(M++Na)。
1H−NMR(CD3OD):δ1.3−1.9(m,36H),2.21(brs,10H),2.57(brs,2H),2.94(brs,12H),5.3−5.6(m,5H),5.68(s,1H)
MS(FAB)m/z881.53(M++Na)。
1H−NMR(CDCl3):δ1.1−1.7(m,144H),2.21(app dd,J=11.4,J=6.8Hz,10H),2.48(t,J=7.4Hz,2H),3.04(app q,J=6.2Hz,12H),5.09(dd,J=10.4,J=2.4Hz,2H),5.18(t,J=9.7Hz,1H),5.47(t,J=10.1Hz,2H),5.57(s,1H),8.3(s,6H,NH),11.5(s,6H,NHBoc)
MS(FAB)m/z2312.34(M++H)。
1H−NMR(CD3OD):δ1.1−2.8(m,48H),3.0(m,12H),5.23(m,6H)
MS(FAB)m/z1111.58(M++H)。
中間体としてD−アルジトール及びmyo−イノシトール異性体をそれぞれ適用することを除いて、製造例6に記載の側鎖化合物を用いて、実施例6−5と同様の方法によって、実施例8−3及び実施例9−3で得たものと同様の6つのグアニジン基を有するアルジトール及びイノシトール誘導体化合物(式12及び13)を製造した。
1H−NMR(CD3OD):δ1.31−1.56(m,36H),2.34(s,12H),3.15(s,12H),5.62(s,6H)
MS(MALDI−TOF)m/z1111.77(M++H)。
前記実施例で製造された、ダンシル(dansyl)蛍光物質を有するそれぞれの化合物に対する細胞膜及び核膜の透過性を測定し、効率的に生体膜を透過することが知られるアルギニン9量体(d−Arg9、dansyl−Arg9;Peptron社製)と、またグアニジン基を有しない中間体と比較した。
実施例9または10の化合物と、蛍光標識されたcAMPまたはオリゴヌクレオチドとのイオン複合体(電荷基準の組成比1:1〜10:1)を製造し、試験例1と同様な方法で細胞膜透過性の実験を行った。共焦点顕微鏡で観察し、結果を図2に示した。
Claims (31)
- ソルビトール、マンニトールまたはガラクチトールの骨格を有するアルジトール誘導体である、請求項1に記載の糖アルコール誘導体、またはその塩。
- 前記式7から9の化合物が、myo−またはscyllo−イノシトール異性体の骨格を有する、請求項4に記載の糖アルコール誘導体、またはその塩。
- 前記式10の化合物がスクロースの骨格を有する、請求項7に記載の二糖類誘導体、またはその塩。
- 前記式11の化合物がα−ラクトース、β−ラクトースまたはマルトースの骨格を有する、請求項7に記載の二糖類誘導体、またはその塩。
- ソルビトール、マンニトールまたはガラクチトールの骨格を有するアルジトール誘導体である、請求項10に記載の糖アルコール誘導体、またはその塩。
- 前記式13または14の化合物が、myo−またはscyllo−イノシトール異性体の骨格を有する、請求項13に記載の糖アルコール誘導体、またはその塩。
- 前記段階1)及び2)が、末端アミノ酸側鎖に保護されたグアニジン基を導入し、および、アシル化反応によって、保護された中間体のヒドロキシル基にグアニジン基を有する側鎖を導入する段階に置き換えられる、請求項15、17、19、21または23に記載の方法。
- 前記生理活性分子が、分子量100から1500g/molの有機化合物である、請求項26に記載の組成物。
- 前記生理活性分子がペプチドおよび核酸である、請求項26に記載の組成物。
- 前記式1、2または3の化合物が、共有結合により前記生理活性分子と共有結合体(conjugate)を形成する、請求項26に記載の組成物。
- 前記式1、2または3の化合物が、イオン結合により前記生理活性分子とイオン複合体(ionic complex)を形成する、請求項26に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050035410A KR100699279B1 (ko) | 2005-04-28 | 2005-04-28 | 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법 |
KR10-2005-0035410 | 2005-04-28 | ||
PCT/KR2005/002040 WO2006115312A1 (en) | 2005-04-28 | 2005-06-29 | Molecular transporters based on sugar and its analogues and processes for the preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008539226A JP2008539226A (ja) | 2008-11-13 |
JP4955659B2 true JP4955659B2 (ja) | 2012-06-20 |
Family
ID=37214915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008508732A Active JP4955659B2 (ja) | 2005-04-28 | 2005-06-29 | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 |
Country Status (5)
Country | Link |
---|---|
US (3) | US7846975B2 (ja) |
EP (1) | EP1885735B1 (ja) |
JP (1) | JP4955659B2 (ja) |
KR (1) | KR100699279B1 (ja) |
WO (1) | WO2006115312A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100849033B1 (ko) * | 2006-09-07 | 2008-07-29 | 포항공과대학교 산학협력단 | 알디톨 또는 이노시톨 유도체를 골격으로 한 분자 수송체 |
US7973084B2 (en) * | 2005-04-28 | 2011-07-05 | Postech Academy-Industrial Foundation | Molecular transporters based on alditol or inositol and processes for the preparation thereof |
EP1996236A2 (en) | 2006-03-22 | 2008-12-03 | National Institute of Immunology | Novel bioconjugates as therapeutic agent and synthesis thereof |
KR101021078B1 (ko) | 2008-07-22 | 2011-03-14 | 포항공과대학교 산학협력단 | 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물 |
CN102268108B (zh) * | 2011-05-13 | 2013-04-10 | 中科院广州化学有限公司 | 一种含氟丙烯酸酯型atrp小分子引发剂及其制备方法 |
BR112014000324A8 (pt) * | 2011-07-19 | 2019-01-29 | Cellmosaic Inc | reagentes reticulantes, macromoléculas, conjugados terapêuticos e métodos sintéticos dos mesmos |
US9511150B2 (en) | 2011-07-19 | 2016-12-06 | CellMosaic, Inc. | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof |
KR20160001419A (ko) * | 2014-06-27 | 2016-01-06 | 포항공과대학교 산학협력단 | 양이온성 분자 수송체 및 음이온성 생리활성 물질을 포함하는 피부 투과용 조성물 |
CZ306254B6 (cs) * | 2015-08-30 | 2016-11-02 | University of Jyväskylä, Department of Chemistry | Transportér nukleotidových struktur |
CA3061612A1 (en) * | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
WO2019036000A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
CZ308447B6 (cs) * | 2018-07-04 | 2020-08-26 | Vysoká škola chemicko-technologická v Praze | Transportéry nukleotidových struktur na bázi hydrazonů jako terapeutický nástroj pro cílení léku pro nádorovou imunoterapii |
WO2022173199A1 (ko) * | 2021-02-15 | 2022-08-18 | 주식회사 바이오파마 | 양이온성 분자 수송체 및 sars-cov-2 mrna의 이온 복합체를 포함하는 코로나바이러스감염증-19 예방 백신 조성물 |
WO2024144348A1 (ko) * | 2022-12-29 | 2024-07-04 | 주식회사 바이오파마 | 양이온성 분자 수송체 및 mrna의 이온복합체를 포함하는 백신 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1979000515A1 (en) | 1978-01-16 | 1979-08-09 | Univ Boston | Method of effecting cellular uptake of molecules |
US5270181A (en) | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
ES2123062T3 (es) | 1992-08-21 | 1999-01-01 | Biogen Inc | Polipeptidos de transporte derivados de la proteina tat. |
DE69422163T2 (de) * | 1993-02-19 | 2000-06-15 | Nippon Shinyaku Co., Ltd. | Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung |
JPH0726298A (ja) * | 1993-07-15 | 1995-01-27 | Lion Corp | 洗浄剤組成物 |
ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
FR2763943B1 (fr) | 1997-05-28 | 1999-07-09 | Rhone Poulenc Rorer Sa | Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules |
EP1206283A2 (en) * | 1999-05-17 | 2002-05-22 | Aesgen, Inc. | Improved cellular uptake of bioactive agents |
KR100374966B1 (ko) * | 2000-06-15 | 2003-03-06 | (주) 제삼교육 | 위치 추적 시스템 및 그 추적 방법 그리고 그 추적 방법이기록된 판독 가능한 기록매체 |
KR100578732B1 (ko) * | 2004-03-05 | 2006-05-12 | 학교법인 포항공과대학교 | 분자 수송체로서의 이노시톨 유도체 및 이의 제조방법 |
KR100849033B1 (ko) * | 2006-09-07 | 2008-07-29 | 포항공과대학교 산학협력단 | 알디톨 또는 이노시톨 유도체를 골격으로 한 분자 수송체 |
-
2005
- 2005-04-28 KR KR1020050035410A patent/KR100699279B1/ko active IP Right Grant
- 2005-06-29 EP EP05756712.5A patent/EP1885735B1/en not_active Ceased
- 2005-06-29 WO PCT/KR2005/002040 patent/WO2006115312A1/en active Application Filing
- 2005-06-29 JP JP2008508732A patent/JP4955659B2/ja active Active
- 2005-06-29 US US11/815,339 patent/US7846975B2/en active Active
-
2010
- 2010-08-20 US US12/860,439 patent/US8048996B2/en not_active Expired - Fee Related
- 2010-08-20 US US12/860,538 patent/US8058413B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20060112791A (ko) | 2006-11-02 |
US8048996B2 (en) | 2011-11-01 |
US8058413B2 (en) | 2011-11-15 |
US7846975B2 (en) | 2010-12-07 |
US20080249296A1 (en) | 2008-10-09 |
EP1885735B1 (en) | 2015-08-05 |
KR100699279B1 (ko) | 2007-03-23 |
EP1885735A4 (en) | 2012-07-25 |
US20100330671A1 (en) | 2010-12-30 |
US20100330608A1 (en) | 2010-12-30 |
JP2008539226A (ja) | 2008-11-13 |
WO2006115312A1 (en) | 2006-11-02 |
EP1885735A1 (en) | 2008-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4955659B2 (ja) | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 | |
AU606909B2 (en) | Sialic acid derivatives having active carbonyl group | |
EP2863925B1 (de) | Sialinsäurederivate | |
DE60027905T2 (de) | Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung | |
McGeary et al. | Carbohydrate-based templates for synthetic vaccines and drug delivery | |
KR100849033B1 (ko) | 알디톨 또는 이노시톨 유도체를 골격으로 한 분자 수송체 | |
EP3274358B1 (en) | Vaccine against carbapenem-resistantklebsiella pneumoniae | |
JP4602991B2 (ja) | イノシトール系分子輸送体及びその製造方法 | |
JP2716657B2 (ja) | 接着分子elam‐1に特異的結合能を有する化合物 | |
US7973084B2 (en) | Molecular transporters based on alditol or inositol and processes for the preparation thereof | |
Greatrex et al. | The synthesis and immune stimulating action of mannose-capped lysine-based dendrimers | |
WO2021193951A1 (ja) | ポリエチレングリコール鎖を有する糖化合物、及び抗体薬物複合体の前駆体 | |
Lee et al. | Mitochondrial affinity of guanidine-rich molecular transporters built on monosaccharide scaffolds: stereochemistry and lipophilicity | |
JP5717281B2 (ja) | ダブルビオチンアンカー型リガンド固定化分子 | |
WO2007048974A2 (fr) | Heterooligomeres de d-glucosamine et n-acetyl-d-glucosamine, leur procede de preparation et leur utilisation | |
WO1998008854A2 (en) | Sugar derivatives as sialyl lewis x mimetics | |
US20090036658A1 (en) | Highly efficient synthesis of alpha-O-galactosyl ceramides | |
ALAGODLA et al. | AJ Csian OURNALOF HEMISTRY AJ Csian OURNALOF HEMISTRY | |
JPH10310596A (ja) | ジガラクトシルセラミド誘導体およびその製造方法 | |
US20040199029A1 (en) | Glycosylation of exo-glycals | |
Paul | Probing receptors and enzymes with synthetic small molecules | |
JPH07109301A (ja) | シアリルルイスx誘導体 | |
JP2006219399A (ja) | 水溶性糖鎖プローブ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100316 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100616 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100708 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110824 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110926 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111024 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4955659 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150323 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |